All News

Found 83 articles

• Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021 Emerging Growth Virtual Conference

  3/11/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that it will present at the Maxim Group Inaugural Emerging Growth Virtual Conference hosted by M-Vest.

• Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, will present at the H.C. Wainwright Global Life Sciences Conference,

• Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.

  12/14/2020

  Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Reviva Holdings ”), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“ Tenzing ”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“ Reviva ”), a California-based clinical-stage ph

• Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination

  11/18/2020

  Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases,

• Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Recruitment of Les Funtleyder as Director

  9/14/2020

  Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands ("Tenzing") (NASDAQ:  TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation ("Reviva") and a California-based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic,

• Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Execution of Definitive Agreement and Plan of Merger for Business Combination

  7/21/2020

  Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (" Tenzing ") (NASDAQ:  TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (" Reviva ") and a California -based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas

• 

  BioSpace Movers & Shakers, May 8

  5/8/2020

  Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Spruce Biosciences Strengthens Leadership Team with Appointments of Samir Gharib as CFO and Dasharatha Reddy as VP of Pharmaceutical Development and Manufacturing

  5/6/2020

  Spruce Biosciences , a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, today announced the appointments of Samir Gharib, MBA, CPA, as Chief Financial Officer (CFO), and Dasharatha Reddy, Ph.D., as Vice President, Pharmaceutical Development and Manufacturing. The appointments expand the expertise of Spruce’s leadership team as the company advan

• Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  6/3/2019

  Reviva Pharmaceuticals, Inc. announced that it has successfully completed a pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis.

• Reviva Pharmaceuticals Selected as a Winner of the 2018 Red Herring Top 100 Global Award

  10/29/2018

  Reviva Pharmaceuticals, Inc. announced today that it has been selected as a winner of the 2018 Red Herring Top 100 Global award, which recognizes the leading private companies from North America, Europe, and Asia, celebrating these companies’ innovations and technologies across their respective industries.

• Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  4/10/2018

  IPF is a devastating disease with limited treatment options and no cure.

• Reviva Pharma Announces Successful Completion Of Pre-IND Meeting With FDA On RP5063 For The Treatment Of Pulmonary Arterial Hypertension

  10/17/2017

  Reviva Pharmaceuticals today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with FDA for its lead compound RP5063, which is being developed for the treatment of pulmonary arterial hypertension (PAH).

• Reviva Pharma Announces Addition Of A New Member To Its Board Of Directors

  7/24/2017

• Reviva Pharma Announces Closing Of Bridge Financing And Addition Of A New Member To Its Board Of Directors

  5/22/2017

• Reviva Pharma Receives FDA Orphan Designation For Pulmonary Arterial Hypertension (PAH)

  11/17/2016

• Reviva Pharma Presented RP5063 Preclinical Efficacy Results For Pulmonary Arterial Hypertension At American Thoracic Society Conference 2016

  5/20/2016

• Reviva Pharmaceuticals Inc Reports RP5063 Positive Efficacy Results For Memory Deficits

  10/22/2015

• Reviva Pharmaceuticals Inc Appoints Three New Board Members

  3/11/2015

• Reviva Pharmaceuticals Inc Wins 2014 TiE50 Award

  5/19/2014

• Reviva Pharmaceuticals Inc Announces Successful End-of-Phase 2 Meeting With FDA for RP5063

  11/5/2013